The serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide. The serum concentration of Cerivastatin can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be increased when combined with Rifampicin. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Isradipine. The metabolism of Bicalutamide can be decreased when combined with Ziprasidone. The serum concentration of Bicalutamide can be decreased when it is combined with Bosentan. The serum concentration of Pravastatin can be increased when it is combined with Bicalutamide. The risk or severity of adverse effects can be increased when Cabergoline is combined with Bicalutamide. The serum concentration of Tolvaptan can be increased when it is combined with Bicalutamide. The serum concentration of Bicalutamide can be decreased when it is combined with Tocilizumab. The serum concentration of Terfenadine can be increased when it is combined with Bicalutamide. The serum concentration of Simvastatin can be increased when it is combined with Bicalutamide. The serum concentration of Rilpivirine can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Lopinavir. The metabolism of Bicalutamide can be decreased when combined with Amiodarone. Bevacizumab may increase the cardiotoxic activities of Bicalutamide. The serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib. The serum concentration of Phenprocoumon can be increased when it is combined with Bicalutamide. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Bicalutamide. The serum concentration of Bicalutamide can be decreased when it is combined with Deferasirox. The metabolism of Bicalutamide can be decreased when combined with Nelfinavir. The metabolism of Bicalutamide can be decreased when combined with Darunavir. The serum concentration of Warfarin can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Cyclosporine. The metabolism of Bicalutamide can be increased when combined with Nevirapine. The serum concentration of Bicalutamide can be increased when it is combined with Simeprevir. The metabolism of Bicalutamide can be decreased when combined with Voriconazole. The serum concentration of Bicalutamide can be increased when it is combined with Palbociclib. The serum concentration of Bicalutamide can be increased when it is combined with Ceritinib. The serum concentration of Fluvastatin can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Nefazodone. The metabolism of Bicalutamide can be decreased when combined with Clotrimazole. Oleandrin may decrease the cardiotoxic activities of Bicalutamide. The risk or severity of adverse effects can be increased when Methysergide is combined with Bicalutamide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bicalutamide. Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. The risk or severity of adverse effects can be increased when Metergoline is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Bortezomib. Acetyldigitoxin may decrease the cardiotoxic activities of Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Saquinavir. The serum concentration of Cisapride can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be increased when combined with Rifabutin. The metabolism of Bicalutamide can be decreased when combined with Olaparib. The risk or severity of adverse effects can be increased when Nicergoline is combined with Bicalutamide. The serum concentration of Ubidecarenone can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Clarithromycin. The metabolism of Bicalutamide can be decreased when combined with Dronedarone. The serum concentration of Bicalutamide can be increased when it is combined with Aprepitant. The metabolism of Bicalutamide can be decreased when combined with Ranolazine. The risk or severity of adverse effects can be increased when Bicalutamide is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Pergolide is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Ticlopidine. The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bicalutamide. Digitoxin may decrease the cardiotoxic activities of Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Diltiazem. The metabolism of Bicalutamide can be decreased when combined with Venlafaxine. The risk or severity of adverse effects can be increased when Lisuride is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Atomoxetine. The metabolism of Bicalutamide can be decreased when combined with Verapamil. The metabolism of Bicalutamide can be decreased when combined with Itraconazole. The serum concentration of Bicalutamide can be increased when it is combined with Netupitant. The serum concentration of Bicalutamide can be decreased when it is combined with Siltuximab. The metabolism of Bicalutamide can be decreased when combined with Telaprevir. The serum concentration of Thioridazine can be increased when it is combined with Bicalutamide. The serum concentration of Acenocoumarol can be increased when it is combined with Bicalutamide. The serum concentration of Bicalutamide can be increased when it is combined with Ivacaftor. The serum concentration of Mevastatin can be increased when it is combined with Bicalutamide. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Fosamprenavir. The metabolism of Bicalutamide can be decreased when combined with Ketoconazole. The serum concentration of Pitavastatin can be increased when it is combined with Bicalutamide. The serum concentration of Bicalutamide can be increased when it is combined with Fusidic Acid. The metabolism of Bicalutamide can be decreased when combined with Idelalisib. The serum concentration of Fluindione can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Clemastine. The metabolism of Bicalutamide can be increased when combined with Phenobarbital. The metabolism of Bicalutamide can be decreased when combined with Sildenafil. The metabolism of Bicalutamide can be decreased when combined with Lovastatin. The serum concentration of Bicalutamide can be decreased when it is combined with Mitotane. Deslanoside may decrease the cardiotoxic activities of Bicalutamide. The serum concentration of Bicalutamide can be increased when it is combined with Luliconazole. The risk or severity of adverse effects can be increased when Ergotamine is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Imatinib. The metabolism of Bicalutamide can be decreased when combined with Cobicistat. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bicalutamide. The serum concentration of Bicalutamide can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Ergonovine is combined with Bicalutamide. The metabolism of Bicalutamide can be increased when combined with Phenytoin. Trastuzumab may increase the cardiotoxic activities of Bicalutamide. The serum concentration of Bicalutamide can be decreased when it is combined with Vemurafenib. The metabolism of Bicalutamide can be decreased when combined with Nilotinib. The metabolism of Bicalutamide can be decreased when combined with Dihydroergotamine. The metabolism of Bicalutamide can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Docetaxel is combined with Bicalutamide. The serum concentration of Bosutinib can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Sulfisoxazole. The metabolism of Bicalutamide can be decreased when combined with Fluconazole. The metabolism of Bicalutamide can be decreased when combined with Erythromycin. The metabolism of Bicalutamide can be decreased when combined with Boceprevir. The serum concentration of Ibrutinib can be increased when it is combined with Bicalutamide. The therapeutic efficacy of Bicalutamide can be decreased when used in combination with Sarilumab. Digoxin may decrease the cardiotoxic activities of Bicalutamide. Proscillaridin may decrease the cardiotoxic activities of Bicalutamide. The serum concentration of Rosuvastatin can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be increased when combined with Rifapentine. The metabolism of Bicalutamide can be increased when combined with Pentobarbital. Ouabain may decrease the cardiotoxic activities of Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Delavirdine. The serum concentration of Bicalutamide can be decreased when it is combined with St. John's Wort. Cyclophosphamide may increase the cardiotoxic activities of Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Posaconazole. The metabolism of Bicalutamide can be decreased when combined with Telithromycin. The serum concentration of Metoprolol can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Indinavir. The metabolism of Bicalutamide can be decreased when combined with Doxycycline. The serum concentration of Cilostazol can be increased when it is combined with Bicalutamide. The serum concentration of Bicalutamide can be increased when it is combined with Stiripentol. The metabolism of Bicalutamide can be increased when combined with Fosphenytoin. The metabolism of Bicalutamide can be increased when combined with Carbamazepine. The serum concentration of Phenindione can be increased when it is combined with Bicalutamide. The serum concentration of Dicoumarol can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Fluvoxamine. The metabolism of Bicalutamide can be decreased when combined with Rucaparib. The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Bicalutamide. The metabolism of Bicalutamide can be decreased when combined with Isavuconazonium. The serum concentration of Bicalutamide can be increased when it is combined with Dasatinib. The serum concentration of Bicalutamide can be increased when it is combined with Osimertinib. The serum concentration of Bicalutamide can be increased when it is combined with Fosaprepitant. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Bicalutamide.